BHLHA9: A Potential Drug Target and Biomarker (G727857)

Target Name: BHLHA9

NCBI ID: G727857

BHLHA9

BHLHA9: A Potential Drug Target and Biomarker

BHLHA9 (Brain-Derived Hippocampal Antigen 9) is a protein that is expressed in the hippocampus, which is the part of the brain that is responsible for memory and learning. BHLHA9 has been identified as a potential drug target (or biomarker) due to its involvement in several neurological conditions, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

One of the main reasons for the potential drug targeting of BHLHA9 is its role in the development and progression of neurodegenerative diseases. Alzheimer's disease is the most common form of dementia, and it is characterized by the progressive accumulation of beta-amyloid plaques in the brain. Beta-amyloid plaques are thought to contribute to the neurotoxicity of Alzheimer's disease, and blocking the function of BHLHA9 has been shown to have potential therapeutic benefits.

Another potential drug target for BHLHA9 is its role in the development of Parkinson's disease. Parkinson's disease is characterized by the progressive loss of dopamine-producing neurons in the brain. The neurotoxicity of alpha-synuclein, a protein that is thought to contribute to the development of Parkinson's disease, has been shown to be associated with the dysfunction of BHLHA9.

In addition to its potential role in neurodegenerative diseases, BHLHA9 has also been identified as a potential biomarker for several other neurological conditions, including schizophrenia. The neurotoxicity of the neurotransmitter dopamine has been shown to be associated with the dysfunction of BHLHA9 in both normal and schizophrenic individuals.

The identification of BHLHA9 as a potential drug target and biomarker has led to a significant increase in research into its function and potential therapeutic applications. Further studies are needed to fully understand the role of BHLHA9 in neurodegenerative diseases and to develop safe and effective treatments.

In conclusion, BHLHA9 is a protein that has been identified as a potential drug target (or biomarker) due to its involvement in several neurological conditions, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Further research is needed to fully understand its function and potential therapeutic applications.

Protein Name: Basic Helix-loop-helix Family Member A9

Functions: Transcription factor, which play a role in limb development. Is an essential player in the regulatory network governing transcription of genes implicated in limb morphogenesis

The "BHLHA9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BHLHA9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets